Adoptive Immunotherapy and High-Risk Myeloma

Despite significant improvements in the treatment of multiple myeloma (MM), it remains mostly incurable, highlighting a need for new therapeutic approaches. Patients with high-risk disease characteristics have a particularly poor prognosis and limited response to current frontline therapies. The rec...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2023-05, Vol.15 (9), p.2633
Hauptverfasser:	Duane, Catherine, O'Dwyer, Michael, Glavey, Siobhan
Format:	Artikel
Sprache:	eng
Schlagworte:	Adoptive immunotherapy Bone cancer Bone marrow Carfilzomib Chimeric antigen receptors Clinical outcomes Clinical trials Cytogenetics Development and progression Drug therapy Health aspects Hematology Immunotherapy Induction therapy Leukemia Lymphocytes Lymphocytes T Medical prognosis Medical treatment Monoclonal antibodies Multiple myeloma Mutation Natural killer cells Patients Plasma Quality of life Response rates Review Risk groups T cell receptors T cells Working groups
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!